Compare · IOVA vs XBIO

IOVA vs XBIO

Side-by-side comparison of Iovance Biotherapeutics Inc. (IOVA) and Xenetic Biosciences Inc. (XBIO): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both companies sit in the Health Care sector. IOVA focuses on Biotechnology: Biological Products (No Diagnostic Substances), while XBIO focuses on Biotechnology: Pharmaceutical Preparations.
  • IOVA is the larger of the two at $3.38B, about 937.2x XBIO ($3.6M).
  • IOVA has been more active in the news (14 items in the past 4 weeks vs 6 for XBIO).
  • IOVA has more recent analyst coverage (21 ratings vs 0 for XBIO).
MetricIOVAXBIO
Company
Iovance Biotherapeutics Inc.
Xenetic Biosciences Inc.
Price
-
-
Market cap
$3.38B
$3.6M
1M return
-
-
1Y return
-
-
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NASDAQ
IPO
News (4w)
14
6
Recent ratings
21
0
IOVA

Iovance Biotherapeutics Inc.

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

XBIO

Xenetic Biosciences Inc.

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Latest IOVA

Latest XBIO